Rodin Therapeutics: Alkermes Eyes Brain Disorders and Beyond With $100M Deal for Rodin

Rodin Therapeutics has limited data from human studies about its neurodegeneration drug, but the company's new approach to treating brain disorders has proven attractive enough for Alkermes to plunk down $100 million to buy the startup. According to financial terms announced Monday, the cash sum is an up front payment. Depending on the progress of [...]